AJCC Cancer Staging Atlas 2/e

Combines the AJCC Staging Atlas with a CD containing all images
Users can also import figures into presentations for cancer conferences, grand rounds, presentations, and journal
articles/book chapters
Based on the 7th Edition staging system
Significantly expanded, expertly and beautifully illustrated, The AJCC Cancer Staging Atlas, 2nd Edition, offers more
than 600 illustrations created exclusively for this new edition and is fully updated to reflect the concepts discussed
in the 7th Edition of both the AJCC Cancer Staging Manual and its companion Handbook. This Atlas illustrates the TNM
classifications of all cancer sites and types included in the 7th Edition of the Manual and visually conceptualizes the
TNM classifications and stage groupings. Specifically designed for simplicity and precision, the drawings have been
verified through multi-disciplinary review to ensure accuracy and relevancy for clinical use. Every illustration
provides detailed anatomic depictions to clarify critical structures and to allow the reader to instantly visualize the
progressive extent of malignant disease. In addition, nodal maps are included for each site, appropriate labeling has
been incorporated to identify significant anatomic structures, and each illustration is accompanied by an explanatory
legend.



The AJCC Cancer Staging Atlas, 2nd Edition, is an official publication of the American Joint Committee on Cancer, the
recognized international leader in state-of-the-art information on cancer staging. This Atlas has been created as a
companion to the updated 7th Edition of the AJCC Cancer Staging Manual, which continues to disseminate the importance
of anatomical and pathological staging in the management of cancer. This state-of-the-art, invaluable 2nd Edition
includes a CD containing PowerPoint slides of all illustrations, additional color, and a user-friendly, easy-to-read
layout. The AJCC Cancer Staging Atlas, 2nd Edition will serve as an indispensable reference for clinicians,
registrars, students, trainees, and patients




American Joint Committee on Cancer ?2012 ix
Contents
Preface ........................................ v
Acknowledgment of Contributors ......................................................... vii
PART I........................................................ 1
General Information on Cancer Staging and End-Results Reporting
1. Purposes and Principles of Cancer Staging ......................................... 3
2. Cancer Survival Analysis ......... 23
PART II ...................................................... 33
Head and Neck
3. Lip and Oral Cavity (Nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone,
and cartilage are not included. Staging for mucosal melanoma of the lip and oral cavity is not
included in this chapter ?see Chap. 9.).................................................. 41
4. Pharynx (Nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone, and cartilage
are not included. Staging of mucosal melanoma of the pharynx is not included ?see Chap. 9.) ....................... 55
5. Larynx (Nonepithelial tumors such as those of lymphoid tissue, soft tissue, bone, and cartilage
are not included) ...................... 79
6. Nasal Cavity and Paranasal Sinuses (Nonepithelial tumors such as those of lymphoid tissue,
soft tissue, bone, and cartilage are not included. Staging for mucosal melanoma of the nasal cavity
and paranasal sinuses is not included in this chapter ?see Chap. 9.) .... 91
7. Major Salivary Glands (Parotid, submandibular, and sublingual) ....... 105
8. Thyroid .................................... 113
9. Mucosal Melanoma of the Head and Neck .......................................... 121
PART III ..................................................... 127
Digestive System
10. Esophagus and Esophagogastric Junction (Nonmucosal cancers are not
included) ......................................... 129
11. Stomach (Lymphomas, sarcomas, and carcinoid tumors [low-grade neuroendocrine tumors]
are not included) ...................... 143
12. Small Intestine (Lymphomas, carcinoid tumors, and visceral sarcomas are not
included) ................................ 155
13. Appendix (Carcinomas and carcinoid tumors of the appendix are included,
but separately categorized) ....... 169
14. Colon and Rectum (Sarcomas, lymphomas, and carcinoid tumors of the large intestine
are not included) ...................... 185
15. Anus (The classi fi cation applies to carcinomas only; melanomas, carcinoid tumors,
and sarcomas are not included.) ............................................................ 203
x American Joint Committee on Cancer ?2012
16. Gastrointestinal Stromal Tumor ........................................................... 215
17. Neuroendocrine Tumors (Gastric, small bowel, colonic, rectal, and ampulla of vater carcinoid tumors
[well-differentiated neuroendocrine tumors and well-differentiated neuroendocrine carcinomas];
carcinoid tumors of the appendix [see Chap. 13] and neuroendocrine tumors of the pancreas
[see Chap. 24] are not included.) ........................................................... 221
18. Liver (Excluding intrahepatic bile ducts; sarcomas and tumors metastatic to the liver
are not included) ...................... 241
19. Intrahepatic Bile Ducts ........... 251
20. Gallbladder (Carcinoid tumors and sarcomas are not included) .......... 259
21. Perihilar Bile Ducts (Sarcoma and carcinoid tumors are not
included) ............................................................ 269
22. Distal Bile Duct (Sarcoma and carcinoid tumors are not included) ..... 277
23. Ampulla of Vater ..................... 287
24. Exocrine and Endocrine Pancreas ........................................................ 297
PART IV ..................................................... 309
Thorax
25. Lung (Carcinoid tumors are included. Sarcomas and other rare tumors are not
included) ............................... 311
26. Pleural Mesothelioma ............. 329
PART V ...................................................... 339
Musculoskeletal Sites
27. Bone (Primary malignant lymphoma and multiple myeloma are not
included) .............................................. 341
28. Soft Tissue Sarcoma (Kaposi뭩 sarcoma, fi bromatosis [desmoid tumor], and sarcoma arising
from the dura mater, brain, parenchymatous organs, or hollow viscera are not
included) ................................. 349
PART VI ..................................................... 355
Skin
29. Cutaneous Squamous Cell Carcinoma and Other Cutaneous
Carcinomas ................................................... 357
30. Merkel Cell Carcinoma (Staging for Merkel Cell of the eyelid [C44.1] is not included
in this chapter ?see Chap. 48, 밅arcinoma of the Eyelid?in the AJCC Cancer Staging Manual) ..................... 371
31. Melanoma of the Skin ............. 385
PART VII .................................................... 417
Breast
32. Breast ........................................ 419
American Joint Committee on Cancer ?2012 xi
PART VIII ................................................... 441
Gynecologic Sites
33. Vulva (Mucosal malignant melanoma is not included) ......................... 443
34. Vagina....................................... 455
35. Cervix Uteri ............................. 463
36. Corpus Uteri ............................ 477
37. Ovary and Primary Peritoneal Carcinoma .......................................... 495
38. Fallopian Tube ......................... 505
39. Gestational Trophoblastic Tumors ........................................................ 515
PART IX ..................................................... 521
Genitourinary Sites
40. Penis (Primary urethral carcinomas and melanomas are not included) ..........................523
41. Prostate (Sarcomas and transitional cell carcinomas are not included) 535
42. Testis ......................................... 547
43. Kidney ...................................... 557
44. Renal Pelvis and Ureter ........... 567
45. Urinary Bladder ....................... 575
46. Urethra ..................................... 583
47. Adrenal ..................................... 595
PART X ...................................................... 601
Lymphoid Neoplasms
48. Hodgkin and Non-Hodgkin Lymphomas (Excludes ocular adnexal lymphoma) ........................................... 605
49. Primary Cutaneous Lymphomas .......................................................... 619
Index .... 627